Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
7683-36-5
Molecular formula
C14H16N4O3+2
Molecular weight
288.3 g/mol
Drug class
Oxime antidoteacetylcholinesterase reactivator for organophosphate poisoning
Mechanism of action
Provides an oxime group that can bind to the phosphorylated active site of acetylcholinesterase and promote dephosphorylation before enzyme ageing occurs, restoring cholinesterase activity. Reactivation effectiveness depends on the specific organophosphate and timing.
Indications / reported uses
Adjunctive treatment of poisoning with susceptible organophosphorus compounds, together with atropine, decontamination and supportive care, using the locally authorised product and toxicology protocol.
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Obidoxime PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Obidoxime Permitted Daily Exposure (PDE) report (the Obidoxime PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Obidoxime Occupational Exposure Limit (OEL) report (the Obidoxime OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.